Table 1.
Demographic features of a total of 92 patients with UC
| Characteristics | N=92 |
|---|---|
| Age(year), mean(range)±SD | 48.5 (14-83) ±16.3 |
| Male/Female, n(%) | 64/28 (69.6/30.4) |
| Disease duration(year), mean(range)±SD | 7.2 (0.1-26) ± 7.1 |
| Disease extent, n(%) | |
| Extensive colitis | 57 (63.0) |
| Left sided colitis | 24 (26.1) |
| Proctitis | 11 (10.9) |
| CAI(Lichtiger socre) mean(range)±SD | 3.4 ± 4.3 |
| eMayo mean(range)±SD | 1.0 (0-3) ±1.0 |
| eMayo 0, n (%) | 38 (41.3) |
| eMayo 1, n (%) | 21 (22.8) |
| eMayo 2, n (%) | 27 (29.3) |
| eMayo 3, n (%) | 6 (6.6) |
| UCEIS mean(range)±SD | 2.1 (0-7) ± 1.9 |
| PGE-MUM (μ·g-1·Cr-1) mean(range)±SD | 29.2 (5.1-93.9) ± 18.5 |
| Fecal hemoglobin concentrations (ng/ml), n (%) mean(range)±SD | 2178 (0-26500) ± 4667 |
| Drug at study, n (%) | |
| Oral 5-ASA | 58 (63.0) |
| Suppository 5-ASA | 12 (13.0) |
| Systemic steroids | 12 (13.0) |
| Azathioprine / Mercaptopurine | 35 (38.0) |
| Tacrolimus | 10 (10.9) |
| Biologics | 25 (27.2) |
CAI clinical activity index, eMayo Mayo endoscopic subscore, UCEIS Ulcerative Colitis Endoscopic Index of severity, PGE-MUM Prostaglandin E-Major Urinary Metabolite, 5-ASA 5-aminosalicylic acid